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Inulavosin, a Melanogenesis Inhibitor, Leads to
Mistargeting of Tyrosinase to Lysosomes and
Accelerates its Degradation
Hideaki Fujita1,6, Tomonori Motokawa2,6, Takayuki Katagiri2, Sadaki Yokota3, Akitsugu Yamamoto4,
Masaru Himeno5 and Yoshitaka Tanaka1
Themelanosome is a highly specialized organelle where melanin is synthesized. Tyrosinase and tyrosinase-related
protein-1 (Tyrp1) are major melanosomal membrane proteins and key enzymes for melanin synthesis in
melanocytes. Inulavosin, a melanogenesis inhibitor isolated from Inula nervosa (Compositae), reduced the
melanin content without affecting either the enzymatic activities or the transcription of tyrosinase or Tyrp1 in B16
melanoma cells. To our knowledge, this inhibitor is previously unreported. Electron-microscopic analyses
revealed that inulavosin impaired late-stage development of melanosomes (stages III and IV), in which melanin is
heavily deposited. However, it did not alter the early stages of melanosomes (stages I and II), when filamentous
structure is observed. Immunofluorescence analyses showed that tyrosinase, but not Tyrp1, was specifically
eliminated from melanosomes in cells treated with inulavosin. Unexpectedly, inulavosin specifically accelerated
the degradation of tyrosinase but not other melanosomal/lysosomal membrane proteins (Tyrp1, Pmel17, and
LGP85). The degradation of tyrosinase induced by inulavosin associated with lysosomes but not the proteasome.
Interestingly, lysosomal protease inhibitors restored the melanogenesis but not the targeting of tyrosinase to
melanosomes in the cells treated with inulavosin. Instead, colocalization of tyrosinase with lysosome-associated
membrane protein-1 at late endosomes/multivesicular bodies and lysosomes was accentuated. Taken together,
inulavosin inhibits melanogenesis as a result of mistargeting of tyrosinase to lysosomes.
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INTRODUCTION
The melanosome is a highly specialized organelle where
melanin is synthesized and deposited on the internal matrix
(Orlow, 1995; Marks et al., 2001; Raposo and Marks, 2002;
Dell’Angelica, 2003). Four distinct but successive morphologi-
cal stages of melanosome maturation can be seen in
melanocytes. Vesicular structures containing no visible pig-
ment but with internal matrix materials are the defining feature
of stage I and constitute the premelanosomal compartment.
The maturation of premelanosomes to stage II melanosomes
accompanies both elongation of the vesicular structures to
oval-shaped ones and ordering of internal filaments into
parallel arrays. Stage III melanosomes are easily distinguished
by the presence of ordered deposits of melanin (sometimes
appearing as black beads on a string) on the internal filaments.
Finally, stage IV melanosomes are completely filled with
melanin, and thus no internal structures are visible in them.
Several melanosomal membrane proteins, such as tyrosi-
nase, tyrosinase-related protein-1 (Tyrp1), tyrosinase-related
protein 2/Dopachrome tautomerase (Tyrp2/DCT), and
Pmel17 (del Marmol and Beermann, 1996), are known to
regulate melanogenesis, as their mutations alter the coat
color in mice and/or result in human genetic disorders,
including oculocutaneous albinism. Both Tyrp1 and Tyrp2/
DCT share about 40% amino-acid homology with tyrosinase,
and have similar structural features, for example, two copper-
binding sites, two cysteine-rich regions, an N-terminal signal
sequence, and a transmembrane domain near the C terminus
(del Marmol and Beermann, 1996). Tyrp1 and Tyrp2/DCT
have been shown to regulate the later stages of the
melanogenesis cascade by regulating dihydroxyindole-
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2-carboxylic acid oxidase and dopachrome tautomerase acti-
vities, respectively. Pmel17 localizes to the intralumenal
membrane vesicles and striations of premelanosomes in
melanocytes (Raposo et al., 2001). Interestingly, overexpres-
sion of Pmel17 in non-pigmented cells causes the formation of
intralumenal striations in multivesicular bodies (MVBs) that
resemble premelanosomal structures (Berson et al., 2001).
Thus, Pmel17 is responsible for the organization of the
architecture of melanosomes rather than for melanin
production. Although the melanogenic function of these
melanosomal membrane proteins is localized in their amino-
terminal domains, which reside within the lumen of melano-
somes, their sorting and targeting signals are located in their
cytoplasmic domains. However, this is not entirely true, as the
sorting of Pmel17 into intralumenal membranes is dependent
on a lumenal sorting signal (Hoashi et al., 2006; Theos et al.,
2006), and a recent report suggests that Tyrp1 also contains a
lumenal sorting signal (Groux-DeGroote et al., 2008).
The trans-Golgi network (TGN) is the primary sorting
place from which proteins are delivered to either the cell
surface or the lysosome (Kornfeld and Mellman, 1989;
Gruenberg and Maxfield, 1995). Recent work from many
laboratories has shown that early endosomes, but not the
TGN, are the major site for sorting of melanosomal proteins
from those destined for lysosomes or elsewhere in the cell
(Raposo and Marks, 2007). Both melanosomal and lysosomal
membrane proteins possess common targeting motifs within
the cytoplasmic region, the so-called tyrosine-based motif
(YXXF-motif) and the di-leucine one (LL-motif) (Bonifacino
and Traub, 2003). At TGN and/or early endosomes, hetero-
tetrameric adaptor protein complexes (APs), known as AP-1
and AP-3, interact with YXXF- and LL-motifs with different
affinity and subsequently sort them to distinct destinations
(Fujita et al., 1999; Robinson and Bonifacino, 2001). As
tyrosinase and Tyrp1 have both YXXF- and LL-motifs within
one molecule, analysis of their targeting signals and/or the
trafficking routes to melanosomes is complicated. It is most
likely that tyrosinase uses both types of targeting signals,
whereas Tyrp1 uses only the LL-motif (Vijayasaradhi et al.,
1995; Calvo et al., 1999; Simmen et al., 1999). In most cases,
both melanosomal and lysosomal membrane proteins suffer
similar trafficking defects on mutation of AP-3 genes, such as
those in the mocha and pearl mutants in mice (Kantheti et al.,
1998; Yang et al., 2000). They mislocalize to the cell surface
and non-endosomal compartments under the plasma mem-
brane (PM). Besides AP-3 (mocha and pearl), there are many
coat color mutations found in the cytosolic machinery that
mediate the sorting and targeting of melanosomal membrane
proteins to melanosomes (Wei, 2006). Many of the gene
products causing coat color mutation in mice have human
counterparts, and some of their genetic mutations relate to
the Hermansky–Pudlak syndrome subtypes; for instance,
mutations found in the AP-3 b-subunit correspond to pearl
in mice and Hermansky–Pudlak syndrome-2 in humans,
respectively (Wei, 2006). These lines of evidence suggest that
the proper targeting of proteins to melanosome is essential
not only for melanogenesis but also for formation of
lysosome-related organelles.
In this study, we found that inulavosin, which is previously
unreported as a melanogenesis inhibitor, specifically
redirects tyrosinase to lysosomes and destabilizes it. Melano-
somes are overlapping but distinct compartments from
lysosomes in melanocytes (Fujita et al., 2001; Raposo and
Marks, 2002). Although melanosomes promote effective
melanin synthesis, lysosomes act as a degradation compart-
ment for melanosomal membrane proteins and thus function
in the downregulation of melanin synthesis. Our data suggest
that lysosomes make a significant contribution to the
regulation of melanogenesis in melanocytes through mem-
brane trafficking and protease activity.
RESULTS
Inulavosin reduces both cell pigmentation and the cellular
content of tyrosinase
Inulavosin (20-hydroxy-2,4,4,7,40-pentamethylflavan) was ori-
ginally identified by Yoshida et al. (1995) as a natural
compound derived from plants that showed both fish toxin
activity and antibacterial activity. Here, we have shown that
it also leads to hypo-pigmentation of B16 melanoma cells
without affecting cell viability.
B16 melanoma cells were exposed to inulavosin at various
concentrations ranging from 5–15 mM for 8, 12, 18, and
24 hours. Treatment of B16 cells with inulavosin induced
time- and concentration-dependent decreases in the melanin
content (Figure 1a). B16 melanoma cells treated with
inulavosin for these indicated times and at these concentra-
tions also clearly showed hypo-pigmentation (Figure 1b).
With the 24 hours exposure, the decrease was significant at
all concentrations, but inulavosin did not show any effect on
cell viability (Figure 1c). Northern blotting analysis revealed
that the inulavosin-induced decrease in the tyrosinase protein
level was not because of a change in the tyrosinase mRNA
level. Inulavosin treatment did not affect the transcription of
tyrosinase or Tyrp1 mRNA (Figure 1d). Therefore, we tested
the stability of the melanosomal membrane proteins tyrosi-
nase and Tyrp1 in the cells treated with inulavosin. The cell
lysates prepared from the cells treated with 15 mM inulavosin
from 24 to 72 hours were analyzed by Western blotting with
antibodies against tyrosinase, Tyrp1, LGP85, a lysosomal
membrane glycoprotein (Fujita et al., 1991), and a-tubulin
(Figure 1e). We found that inulavosin specifically reduced the
cellular content of tyrosinase, but not those of Tyrp1 or
LGP85. The levels of tyrosinase did not rise till 72 hours,
suggesting that inulavosin is stable and functions in B16
melanocytes at least for 72 hours. a-tubulin was used as an
internal standard to show that an equal amount of proteins in
each cell lysate was loaded on the gel. The reduction of the
level of tyrosinase by inulavosin was also concentration
dependent (data not shown). Furthermore, the DOPA (3,4-
hydroxyphenylalanine) oxidase activity, which reflects the
activity of tyrosinase in living cells, was analyzed with an in-
gel DOPA-staining assay. This assay showed a decrease in
the DOPA oxidase activity after 9 hours or longer exposure to
15 mM inulavosin (Figure 1f). Interestingly, inulavosin did not
interfere with the enzyme activities of tyrosinase, Tyrp1 (5,6-
dihydroxyphenylalanine; DHICA oxidase) or Tyrp2 (DOPA
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chrome tautomerase) in vitro (T. Katagiri, unpublished). Thus,
inulavosin-induced hypo-pigmentation is most likely because
of the destabilization of the tyrosinase protein in B16
melanoma cells.
Inulavosin impairs melanin deposition in melanosomes but not
the formation of internal striations of melanosomes
The hypo-pigmentation of melanoma cells induced by
inulavosin was further investigated by electron microscopy.
In control cells, there was accumulation of late-stage
melanosomes (stages III and IV) depositing melanin. They
were often localized near the PM (Figure 2a) and concen-
trated at the tip of the melanocyte (Figure 2b). Sometimes, the
internal matrices of melanosomes, filamentous structures
highly decorated with melanin and not surrounded by
membrane, were found outside of cells (Figure 2c). They
may have represented the secretion of melanosomal contents,
which are transferred to the adjacent keratinocyte cells in
normal skin tissue (Okazaki et al., 1976). The early-stage
melanosomes (stages I and II), which contained the internal
matrix or vesicles without melanin deposition, were localized
inside of cells, close to the nucleus. Interestingly, the cells
treated with 15 mM inulavosin for 72 hours lacked late-stage
melanosomes, containing melanin deposits, whereas they
had early-stage ones to the same extent as the control cells
(Figure 2c and d). They contained either multivesicular or
filamentous structures and sometimes formed oval-shaped
structures without melanin deposition (Figure 2d asterisks).
There was no significant structural alteration of the melano-
somes in the cells treated with inulavosin, except for the lack
of melanin deposition in them. Other organelles, notably the
Golgi apparatus, mitochondria, and the nucleus, were not
affected by treatment with inulavosin.
Inulavosin alters the intracellular localization of tyrosinase from
melanosomes to the TGN
We next investigated the effect of inulavosin on the
intracellular localization of tyrosinase, Tyrp1, and lyso-
some-associated membrane protein-1 (lamp1) by immuno-
fluorescence analyses (Figure 3a). Tyrosinase predominantly
localized to melanosomes, punctate structures spread
throughout the cytoplasm and peripheral region in control
melanocytes. Most of the heavily melanized melanosomes,
identified as black granules by phase contrast observation,
were stained with anti-tyrosinase antibody (data not shown).
However, some other punctate structures immunostained
with anti-tyrosinase antibody besides melanosomes were
partially colocalized with lamp1, a marker of both late
endosomes and lysosomes (Fujita et al., 2001). In addition,
the anti-tyrosinase antibody showed perinuclear staining that
was colocalized with syntaxin 6, a marker of the TGN (Figure
3b; control). Thus, tyrosinase was identified in most of the
post-Golgi compartments, including the TGN, late endo-
somes, lysosomes, and melanosomes in melanocytes. In cells
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Figure 1. Inulavosin inhibits cellular pigmentation and specifically decreases the intracellular content of tyrosinase in B16 melanoma cells. (a) B16 melanoma
cells were incubated with 5–15 mM inulavosin for the indicated times (h) before preparing cell extracts. Melanin content assays were performed as described in
Materials and Methods. The calculated melanin content was expressed relative to that of non-treated cells. Values represent the mean±SD. (b) B16 melanoma
cells were treated with 15 mM inulavosin for the indicated times or treated for 24 hours with the indicated concentration of inulavosin, and then the cells were
collected by centrifugation. (c) After 24 hour treatment with inulavosin, B16 cells were collected to determine the cell number, which was expressed relative to
the number of non-treated cells. Values represent the mean±SD. (d) B16 melanoma cells were incubated with 5–15 mM inulavosin for 3 or 6 hours before
preparing cell extracts for Northern blotting to observe the effect on tyrosinase and Tyrp1 mRNAs. Total RNA prepared from the cells treated with the indicated
concentration of inulavosin in duplicate was electrophoresed in the gel, blotted to the membrane, and probed with P32-labeled probes. (e) The cell lysates
prepared from cells treated with inulavosin for the indicated times (h) were subjected to SDS-PAGE and processed for immunoblotting with antibodies against
tyrosinase, Tyrp1, LGP85, or a-tubulin as indicated. (f) B16 melanoma cells were incubated with 5–15 mM inulavosin for the indicated times before preparing cell
extracts. To observe tyrosinase activity in living cells, in-gel DOPA-stain assay was performed in duplicate.
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treated with 15 mM inulavosin for 24 hours, the localizations
of Tyrp1, lamp1, and syntaxin 6 were not changed (Figure 3a
and b; inulavosin). In contrast, tyrosinase was clearly
eliminated from melanosomes and detected only at the
tubular structures adjacent to the nucleus in the cells treated
with inulavosin. Intriguingly, tyrosinase was completely
colocalized with syntaxin 6 at the TGN (Figure 3b;
Inulavosin). Protein trafficking through the Golgi/TGN is
one of the rate-limiting steps in the secretory pathway. Thus,
if cargo molecules are overloaded (ie, overexpressed) and/or
rapidly eliminated from the latter compartments (ie, degraded
or secreted), their residual detection at the Golgi/TGN area is
Control
Tyrosinase
Tyrosinase
Syntaxin 6
lamp 1
Tyrp 1
Phase
Inulavosin
Control
Merge
Inulavosin
Figure 3. Inulavosin specifically alters the intracellular localization of tyrosinase from melanosomes to TGN in B16 melanoma cells. (a) B16 melanoma cells
treated with either DMSO (control) or 15mM inulavosin for 72 hours (inulavosin) were processed for immunofluorescence analysis. Fixed and permeabilized cells
were stained with antibodies to tyrosinase, lamp1, or Tyrp1, and both fluorescence and phase images are shown. (b) Double-labeling with tyrosinase (red in
merged images) and syntaxin 6, TGN marker (green in merged images) in B16 melanoma cells treated with either DMSO (control) or 15mM inulavosin for
72 hours (inulavosin) are shown. Bars, 10 mm.
N
1
2
3*
3*
N
1 4
32
2
1
2
1
GolgiGolgi
3
2
2 4
1
N
Golgi 2
1
21
a b
c d
Figure 2. Inulavosin affects the late stages of melanogenesis but not the early ones in B16 melanoma cells. Control and inulavosin-treated B16 melanoma cells
were processed for electron microscopic analyses. (a), (b) Control cells and (c), (d) cells treated with 15 mM inulavosin for 72 hours. N: nucleus, Golgi: Golgi
apparatus, 1: stage I melanosome—a relatively spherical organelle containing matrix materials (ie, filaments or vesicles); 2: stage II melanosome—an oval-
shaped organelle containing an organized matrix without the appearance of melanin; 3: stage III melanosome—an organelle exhibiting the deposition of
melanin on the matrix; 4: stage IV melanosome—an organelle filled completely with melanin; 3*: an organelle containing well-organized matrix, similar to a
stage III melanosome, but not exhibiting the deposition of melanin. Bars, 1.0mm.
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accentuated. As tyrosinase is one of the major products in
melanocytes (ie, is highly expressed), we assume that the
altered distribution pattern of tyrosinase from melanosomes
to the TGN is most likely a result of its degradation.
Inulavosin specifically accelerates the degradation of tyrosinase
but not Tyrp1, Pmel17, or LGP85
The data described above suggest that inulavosin specifically
affected both the cellular content and intracellular localiza-
tion of tyrosinase. How should these observations be
interpreted? As inulavosin did not affect the transcription of
tyrosinase mRNA, one possibility is that it specifically
accelerated the protein degradation of tyrosinase. To test this
prediction, pulse-chase experiments were performed. In
control cells, pulse-labeled tyrosinase was translated as an
B70 kDa precursor form that was glycosylated as a high-
mannose form and subsequently processed into a complex-
type B76 kDa mature form (Figure 4a; control). It was
gradually degraded even in control cells but remained
detectable at least until 9 hours of chase after pulse labeling.
In contrast, in the cells treated with 15mM inulavosin,
tyrosinase was rapidly degraded and hard to detect at 3 hours
of chase (Figure 4a; inulavosin). Inulavosin has no effect on
the synthesis of tyrosinase (Figure 5; control). These results
suggest that inulavosin accelerated the degradation of newly
synthesized tyrosinase, at least after it exited the endoplasmic
reticulum. Interestingly, inulavosin affected neither the
processing nor the stability of the other melanosomal/
lysosomal membrane proteins examined, Tyrp1, Pmel17,
and LGP85. Both Tyrp1 and LGP85 were synthesized as high-
mannose precursor forms (B70 and B77 kDa, respectively)
and processed into mature forms (B76 and B85 kDa,
respectively) with complex-type carbohydrates after exiting
the endoplasmic reticulum (Xu et al., 1997; Niwa et al.,
2003). Inulavosin has no effect on the syntheses of Tyrp1
(data not shown), Pmel17, and LGP85 (Figure 4b; time 0).
They were stable and showed little degradation during the
9- and 4-hour chase periods, respectively, in either the presence
or absence of inulavosin. Mouse Pmel17 was synthesized as
an 85-kDa P1 form, processed into a 100-kDa P2 form and
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76 kDa
76 kDa
70 kDa
70 kDa
p2: 100 kDa
p1: 85 kDa
85 kDa
77 kDa
9 3 9
10 4 4
PmeI17
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Figure 4. Inulavosin accelerates the degradation of tyrosinase but not of
other melanosomal and lysosomal proteins in B16 melanoma cells. B16
melanoma cells were cultured for 24 hours with either DMSO (control) or
15mM inulavosin, and then pulse-labeled for 10minutes and chased for the
indicated times (h) either in the presence or absence of inulavosin. As
described in Materials and Methods, the radiolabeled proteins were
immunoprecipitated with antibodies to tyrosinase, Tyrp1 (a) or Pmel17,
LGP85 (b).
Control
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Chase
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+–+–+–
Leupeptin/ 
pepstatin A 
(100 μM)
+–+–+–+– : Inulavosin
: Inulavosin
3 hours1 hour
NH4CL
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3 hours1 hour
Epoxomicin
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+–+–+– : Inulavosin
Figure 5. Lysosomal protease inhibitors, but not proteasome inhibitors,
impair the inulavosin-induced degradation of tyrosinase. B16 melanoma
cells were cultured for 24 hours with either DMSO () or 15 mM inulavosin
(þ ). Subsequently, the cells were pulse-labeled for 10minutes and then
chased with the indicated inhibitors (for the lysosomal inhibitors, leupeptin
and pepstatin A (100mM each) or 50mM NH4Cl; and for the proteasome
inhibitors, 5 mM of epoxomicin or lactacystin) either in the presence or
absence of 15mM inulavosin (þ /). As described in Materials and Methods,
the radiolabeled tyrosinase was immunoprecipitated with its specific
antibody.
www.jidonline.org 1493
H Fujita et al.
Inulavosin Leads Tyrosinase to Lysosomes
then rapidly converted to a two-chain form by proteolytic
processing (Berson et al., 2001). Although the antibody to
Pmel17 that we used in this study was unable to detect the
two-chain form, inulavosin did not affect the processing of
Pmel17 from P1 to P2 (Figure 4a). As ultrastructural analysis
revealed that the formation of internal striation in melano-
somes was normal in the cells treated with inulavosin (Figure
2c and d), the further transport, processing, and fiber
formation of Pmel17 appear not to be altered.
Inulavosin-induced degradation of tyrosinase is associated with
lysosomes, but not the proteasome
To determine the site where the degradation of tyrosinase
occurs, pulse-chase experiments with a combination of
inulavosin and lysosomal protease inhibitors or proteasome
inhibitors were performed (Figure 5). In the control cells, a
3-hours chase was sufficient for degradation of most of the
newly synthesized tyrosinase in the presence of inulavosin.
Interestingly, in the presence of lysosomal protease inhibitors,
leupeptin and pepstatin A (100mM each) or NH4Cl (50mM),
inulavosin-induced degradation of tyrosinase was completely
blocked at least until 6 hours of chase. Moreover, the
degradation of tyrosinase that occurred naturally (ie, in the
absence of inulavosin) was also significantly delayed. These
observations suggest that lysosomal activity is tightly asso-
ciated with the degradation of tyrosinase, even at the basal
level. On the other hand, neither epoxomicin (5 mM) nor
lactacystin (5 mM), proteasome inhibitors prevented the
inulavosin-induced degradation of tyrosinase. At this con-
centration (5 mM each), we have observed an accumulation of
ubiquitylated proteins in the cells treated with either
epoxomicin or lactacystin, respectively; thus, they both
efficiently inhibit proteasomal degradation (Figure S1). These
inhibitors also had no effect on the basal rate of degradation
of tyrosinase. Thus, we concluded that the site of degradation
of tyrosinase in the cells treated with inulavosin was
lysosomes. Inulavosin may accelerate the relocalization of
tyrosinase from melanosomes to lysosomes.
Lysosomal protease inhibitors restored the cell pigmentation
but not mistargeting of tyrosinase to MVBs/lysosomes
If the site of degradation of tyrosinase were the lysosome,
lysosomal protease inhibitors would restore cell pigmentation
in the cells treated with inulavosin. As we expected, cells
treated simultaneously with 15 mM inulavosin plus lysosomal
protease inhibitors (20 mM leupeptin and pepstatin A)
showed hyper-pigmentation to the same extent as control
cells (Figure 6a). Double immunofluorescence analysis with
anti-tyrosinase and anti-lamp1 antibodies revealed that
tyrosinase was not colocalized with lamp1, a marker of late
endosomes/MVBs and lysosomes in control cells (Figure 6b
and c; control). They were both found at small dot-like
structures but did not overlap each other; thus, a little yellow-
colored merged area was found in control cells (Figure 6b
and c; control). In the presence of inulavosin, although lamp-
1 positive dot-like structures were not altered, tyrosinase-
positive ones were absent from cytoplasm and only peri-
nuclear structures corresponding to the TGN were retained
(Figure 6b; Inulavosin). This result indicated that inulavosin
led mistargeting of tyrosinase to lysosomes and accelerated
its degradation. Intriguingly, in the presence of both
inulavosin and lysosomal protease inhibitors, tyrosinase
positive dot-like structures were restored and their colocali-
zation with lamp1 was accentuated (Figure 6b and c;
inulavosinþ leupeptin/pepstatin A). Many yellow-colored
merged vesicular structures were observed in the peripheral
region. These results suggested that lysosomal protease
inhibitors can inhibit inulavosin-induced degradation of
Control 
(DMSO) Control (DMSO) Control 
(DMSO)
Inulavosin
Inulavosin
Merge Tyrosinase lamp1 Higher magnification
Inulavosin
+
Leupeptin/
Pepstatin A
Inulavosin
+
Leupeptin/
 Pepstatin A
Inulavosin
+
Leupeptin/
Pepstatin A
Figure 6. Lysosomal protease inhibitors prevent the alteration of melanogenesis but not of the intracellular trafficking of tyrosinase induced by inulavosin
treatment. B16 melanoma cells were cultured for 72 hours in the presence of 15 mM inulavosin either with or without a mixture of the lysosomal protease
inhibitors, leupeptin and pepstatin A (20mM each). The cells were collected by centrifugation (a) or processed for double-immunofluorescence analysis (b, c)
with antibodies to tyrosinase (red) and lamp1 (green). Higher magnification images (c) showed that colocalization of tyrosinase with lamp1 was significantly
accentuated by treatment with inulavosin and lysosomal protease inhibitors. Bars, 10 mm.
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tyrosinase in lysosomes but cannot restore its mistargeting to
lysosomes.
Ultrastructural analysis clearly revealed that heavily
melanized melanosomes (stages III and IV) were not found
in the cells treated with inulavosin and protease inhibitors
(Figure 7b). Instead, there was accumulation of MVBs (Figure
7b; asterisks). Intriguingly, immuno-gold labeling showed
that the localization of tyrosinase (associated with melano-
somes in control cell; Figure 7c) was altered to MVBs in the
cells treated with inulavosin and protease inhibitors (Figure
7d). This may indicate that inulavosin-induced mistargeting
of tyrosinase to MVBs still occurred. Consistent with
immunofluorescence data, double immuno-gold labeling
analyses showed little colocalization of tyrosinase and lamp1
in control cells (Figure 7e), whereas they significantly
colocalized at MVBs in the cells treated with inulavosin
and protease inhibitors (Figure 7f). Intriguingly, tyrosinase is
detected largely on the internal membranes of the MVBs,
whereas lamp1 is detected primarily on the limiting
membrane. This result fits with observations by Theos et al.
(2005), who showed tyrosinase on the internal membranes of
melanosomes in wild-type melanocytes and of MVBs and
early endosomes in AP-3-deficient melanocytes. Taken
together, our findings suggest that the hypo-pigmentation
induced by inulavosin was because of the mistargeting and
degradation of tyrosinase in lysosomes.
DISCUSSION
In this study, we showed that inulavosin, a novel melanogen-
esis inhibitor, redirected tyrosinase to MVBs/lysosomes, and
as a result it caused the hypo-pigmentation of melanocytes.
Lysosomal protease inhibitors prevented the effects of
inulavosin on the cell pigmentation as a result of the
stabilization of tyrosinase. Interestingly, the cells treated with
lysosomal protease inhibitors alone showed both hyper-
pigmentation and stabilization of tyrosinase compared with
control cells (Figures 5 and 6a (leupeptin/pepstatin A); pulse-
chase). These results also suggest that lysosomes are the sites
of degradation of tyrosinase, that is, some tyrosinase is
continuously delivered to and degraded in lysosomes, in
normal melanocytes. Inulavosin enhances the mistargeting of
tyrosinase to MVBs/lysosomes by an unidentified mechanism,
and as a result it accelerates the rate of degradation of
tyrosinase. Re-establishment of pigmentation in the cells
treated with inulavosin and lysosomal protease inhibitors is
an intriguing but confusing result. We speculate that in B16
melanoma cells, the localization of all other melanogenic
enzymes (ie, Tyrp1 and Tyrp2/DCT, etc.) and transporter(s) of
tyrosine substrate are not restricted to late stages of
melanosomes. Small amounts of them, but sufficient enough
to produce melanin, may exist on the way to melanosomes,
such as MVB. Once tyrosinase mislocalizes to MVB by
inulavosin and is stabilized by the protease inhibitors, it may
facilitate the dramatic melanin induction at MVB. Alterna-
tively, in the presence of lysosomal protease inhibitors, not
only tyrosinase but also these enzymes and transporter(s) may
be stabilized. Indeed, our Western blotting analyses revealed
that lysosomal protease inhibitors stabilized both tyrosinase
and Tyrp1 (data not shown). If the basal level of degradation
of melanogenic enzymes and transporter(s) is impaired, they
accumulate and deposit melanin at MVB. These speculations
match with our concept that lysosomes negatively regulate
the melanogenesis in melanocyte.
No ultrastructural alteration (neither shrinkage nor swel-
lings nor aggregation of membranous structures, including
MVBs, melanosomes, Golgi apparatus, nuclear envelopes,
and mitochondria) was found in the cells treated with
inulavosin. One important finding was that inulavosin did
not affect the formation of either MVBs or premelanosomes.
In non-pigmented cells, MVBs are involved in sorting the
Control
(DMSO)
Inulavosin
+
Leupeptin/Pepstation A
Tyrosinase
10 nm Gold
(arrowheads)
Tyrosinase
10 nm Gold
(arrowheads)
lamp1
5 nm Gold
(arrow)
MVB
MVB
MVB
MVB
Melanosome
a b
c
e f
d
Figure 7. Immunoelectron microscopic analysis of tyrosinase in the cells
treated with inulavosin and lysosomal protease inhibitors. B16 melanoma
cells were cultured for 72 hours in the absence (a, c, and e) or presence (b, d,
and f) of lysosomal protease inhibitors (leupeptin and pepstatin A, 20mM each)
with 15mM inulavosin. Then, they were fixed and processed for both electron
microscopic (a and b) and immunoelectron microscopic (c–f) analyses (c and
d, single-labeled with anti-tyrosinase (10 nm gold particles); e and f, double-
labeled with anti-tyrosinase (10 nm gold particles); and anti-lamp1 (5 nm
ones)). Various stages (I–IV) of melanosomes, but MVBs, were found in control
cells (a), whereas MVBs (asterisks) are accumulated, although heavily
melanized melanosomes (stages III and IV) were barely found in the cells
treated with lysosomal protease inhibitors and inulavosin (b). In control cells,
tyrosinase (arrowheads) exclusively localized to heavily melanized
melanosomes (c, e), whereas lamp1 (arrows in e) was found on MVB. In the
cells treated with lysosomal protease inhibitors and inulavosin, tyrosinase
(arrowheads) localized to MVBs (d, f) and colocalized with lamp1 (arrows in
f). Bars, 500 nm in (a and b); 100 nm in (c, d, e, and f).
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membrane proteins into either a recycling route to the PM or
a segregation of them into the inner vesicles that are
ultimately degraded by lysosomal acid hydrolases (Gruen-
berg and Stenmark, 2004). Inulavosin did not interfere with
this process. Inulavosin also did not impair the proteolytic
processing of Pmel17. Although the localization of Pmel17
was not examined, the normal formation of internal striation
in melanosomes might reflect its proper localization and
function in the cells treated with inulavosin. Taken together,
our findings suggest that the target of inulavosin is not
likely to be the molecule(s) that mediate the formation of
MVB structures, such as phosphatidylinositol 3-kinases and
their products (Gruenberg and Stenmark, 2004; Piper and
Katzmann, 2007).
The data obtained so far indicated that the effect of
inulavosin is restricted to the stability of tyrosinase. As
inulavosin does not affect the enzymatic activity of tyrosinase
in vitro, it may not interact directly with tyrosinase. What is
the target molecule(s) of inulavosin? One molecule known to
regulate protein targeting to melanosomes is AP-3. Indeed,
pearl and mocha mouse melanocytes, which have lacked
b3A and d3 subunits of AP-3, respectively, show the hypo-
pigmentation of cells and the mislocalization of tyrosinase to
the PM (Kantheti et al., 1998; Simmen et al., 1999). Both
tyrosinase and Tyrp1 have a similar targeting signal in their
cytoplasmic tails, LL-motifs that are recognized by the AP-3
complex (Honing et al., 1998). However, a recent in vitro
analysis performed by Chapuy et al. (2008) showed that
tyrosinase (and lamp1) require AP-3 for the efficient sorting
into post-Golgi/TGN vesicles, whereas Tyrp1 uses AP-1/
clathrin. Several other reports also indicate that Tyrp1 sorting
to melanosomes does not require AP-3 (Huizing et al., 2001;
Theos et al., 2005; Setty et al., 2007; Groux-DeGroote et al.,
2008), and AP-3-independent routes to melanosomes that are
dependent on other protein complexes targeted by mutation
in Hermansky–Pudlak syndrome models have been verified
(Richmond et al., 2005; Setty et al., 2007). Moreover, Setty
et al. (2007) showed that tyrosinase and Tyrp1 have distinct
sorting mechanisms. As inulavosin specifically affects the
stability and localization of tyrosinase, but Tyrp1, AP-3 may
be the target of inulavosin. However, the cellular localization
and content of AP-3 (s3A and B) were not affected by
inulavosin (H. Fujita and T. Motokawa, unpublished). Thus,
the target(s) of inulavosin is more likely the machinery that
recognizes the specific targeting motif(s) in tyrosinase but not
in Tyrp1. An interesting paper was published recently that
assigns the relevant determinants in tyrosinase and TRP-1 to
the lumenal part of the protein instead of the cytosolic tail
(Groux-DeGroote et al., 2008). In addition, the sorting of
Pmel17 to intralumenal membranes is also dependent on a
lumenal sorting signal (Hoashi et al., 2006; Theos et al.,
2006). According to those views, inulavosin could interfere
with lumenal interactions of tyrosinase and not Tyrp1.
Lipid composition is one of the determining factors
required for both the formation of lipid microdomains and
the sorting of membrane proteins (van der Goot and
Gruenberg, 2002; Gruenberg, 2003). The imbalance of
glycosphingolipids and/or cholesterol caused by either the
genetic defects or the specific inhibitors of their biosynthetic
or metabolizing enzymes is known to impair the membrane
traffic in the post-Golgi compartments (Sillence et al., 2002).
A mutant cell line derived from B16 melanoma cells, GM-95
(Ichikawa et al., 1994), which lacks glucosylceramidetrans-
ferase, exhibits hypo-pigmentation of cells (Sprong et al.,
2001). GM-95 cells are unable to produce any glyco-
sphingolipids derived from glucosylceramide in vivo, and
thus they should have some significant defects in lipid
microdomain-dependent membrane trafficking. Indeed, an
accumulation of tyrosinase, but Tyrp1, in the Golgi was
observed in GM-95 cells (Sprong et al., 2001). Moreover,
their recent report revealed that a significant amount of Tyrp1
also takes an incorrect route (passing over the cell surface)
and localizes to lysosomes in GM-95 cells (Groux-DeGroote
et al., 2008). Either the reintroduction of cDNA-expressing
glucosylceramidetransferase or the exogenous supply of
glucosylceramide restores the cell pigmentation and corrects
the localization of both tyrosinase and Tyrp1. These
observations strongly suggest the involvement of the lipid
microdomain in protein sorting to melanosomes. It has also
been shown that fatty acids themselves affect the stability of
tyrosinase in melanocytes (Ando et al., 1999). Exogenously
applied unsaturated fatty acids (linoleic acid), but not
saturated ones (palmitic acid), specifically lead to the
downregulation (proteolytic degradation) of tyrosinase and
result in the hypo-pigmentation of cells. Interestingly, it does
not affect Tyrp1. It was suggested that a proteasome activity is
involved in the degradation of Tyrp1 (Ando et al., 2004),
although the precise roles of fatty acids are not fully
understood. Moreover, an accumulation of both tyrosinase
and cholesterol in the endosomal/lysosomal compartments is
observed on the treatment of melanocytes with U18666A,
which prevents cholesterol efflux from late endosomes/
lysosomes (Hall et al., 2003). Interestingly, in this case, the
degradation of tyrosinase seems to be minimized, as a
significant colocalization of it with lamp1 is observed in
punctate structures that might be lysosomes. Considering
these findings together, one attractive hypothesis to account
for the effect of inulavosin is that tyrosinase, but not Tyrp1, is
delivered to melanosomes in a lipid microdomain-dependent
manner. So far, we have not been able to detect any
significant alteration of the composition of major lipids
(including ceramide, glucosylceramide, phosphatidyl-etha-
nolamine, phosphatidyl-serine, and sphingomyelin) in B16
melanoma cells treated with inulavosin (T. Katagiri, unpub-
lished data). Further careful analysis to identify lipid(s) or lipid
microdomain component(s) that may be affected by inulavo-
sin needs to be done. Besides fatty acids, there are multiple
agents shown to affect tyrosinase sorting and degradation—
eg, phenylthiourea (Hall and Orlow, 2005), tricyclic anti-
depressants (Ni-Komatsu and Orlow, 2008), and so on
(Solano et al., 2006). A comparison of inulavosin with these
reagents may give us a hint for understanding the molecular
mechanism of melanogenesis.
Finally, our results clearly show that the melanosome is a
distinct compartment from the lysosome in melanocytes
(Raposo et al., 2001). Earlier, we distinguished them either
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by morphological analysis using fluorescence-labeled dex-
tran as a lysosomal marker or by the immunoisolation of
melanosomes and lysosomes using antibodies to the cyto-
plasmic regions of Tyrp1 and LGP85, respectively (Fujita
et al., 2001). The acceleration of the degradation of
tyrosinase induced by inulavosin indicates that tyrosinase is
stable in melanosomes but not in lysosomes. Moreover, the
fact that tyrosinase is degraded in lysosomes at the steady
state level suggests that lysosomes can act as a negative
regulator of cell pigmentation in melanocytes. In post-Golgi
compartments, lysosomes play major roles in the degradation
of not only proteins but also membrane structures, ie,
organelles. Although the biogenesis of melanosomes has
been well delineated, their destruction has not been well
studied yet. The elucidation of the mechanism of action of
inulavosin may shed new light on the roles of lysosomes in
melanogenesis.
MATERIALS AND METHODS
Antibodies and reagents
Rabbit polyclonal antibodies (pAbs) against tyrosinase and Tyrp1 are
described earlier (Fujita et al., 2001). Rabbit pAb against Pmel 17
(aPEP13) was provided by Dr T. Ueno (Juntendo University, Tokyo,
Japan). Rat MAbs against mouse lamp-1 (1D4B) were provided by
Drs T. August (Johns Hopkins University, Baltimore, MD) and
K. Furuta (National Cancer Center Research Institute, Tokyo, Japan).
Rabbit pAb against a-tubulin was provided by Dr D. Murphy (Johns
Hopkins University). The mAb against syntaxin 6 (Transduction
Laboratories, Lexington, KY), Alexa 594- and 488-labeled goat anti-
mouse, anti-rat, and anti-rabbit secondary antibodies (Molecular
Probes, Eugene, OR) were purchased. Pepstatin A and leupeptin,
specific inhibitors of lysosomal aspartic and cysteine proteases,
respectively, were obtained from Peptide Institute Inc. (Osaka,
Japan). Epoxomicin and lactacystin were purchased from Calbio-
chem (San Diego, CA). Protease inhibitor cocktail was obtained from
Sigma-Aldrich (St Louis, MO). Protein-A coupled Sepharose 4B was
purchased from Pharmacia Biotech (Uppsala, Sweden).
Cell culture
B16 mouse melanoma cells were cultured in minimum essential
medium (Sigma-Aldrich) with 10% fetal bovine serum (Life
Technologies, Gaithersburg, MD).
Measurement of melanin contents
B16 cells were dissolved in 1ml of 5% Trichloroacetic acid (TCA),
and incubated on ice for 10minutes. The lysate was centrifuged at
860 g for 10minutes. The precipitate was dissolved in 2ml of 5%
TCA, incubated on ice for 10minutes, and centrifuged at 860 g for
10minutes. The precipitate was dissolved in 2ml of EtOH-ether
(3:1). The resultant solution was centrifuged at 860 g for
10minutes. The precipitate was resuspended in 2ml of ether, and
the resultant solution was centrifuged at 860 g for 10minutes. The
precipitate was air-dried, and resuspended in 0.5ml of 2 N NaOH at
80 1C for 1 hour. The absorbance at 420 nm was measured.
In gel DOPA staining
B16 cells were dissolved in RIPA buffer (150mM NaCl, 1% NP-40,
0.5% deoxycholic acid, 0.1% SDS, 50mM Tris-HCl pH 8.0). The
lysate was centrifuged at 21,500 g for 10minutes. Proteins (30mg)
in the lysate were then separated by 5–20% gradient gel electro-
phoresis. The gel was washed with phosphate-buffered saline (PBS)
(pH 6.8), soaked in 0.1% DOPA in PBS (pH 6.8), and then incubated
at 37 1C for 30minutes.
Western blotting
The cells were lysed with lysis buffer (10mM Tris-HCl (pH 7.4),
0.15M NaCl, 1% Triton-X100, 0.5% sodium deoxycholate, 1mM
EDTA, and protease inhibitor cocktail) and centrifuged in a
microfuge at 21,500 g for 10minutes to remove insoluble
compounds. The cell extracts were subsequently processed for the
determination of the protein concentration using a Bradford protein
assay kit (Bio-Rad Laboratories, Hercules, CA) and BSA as a
standard. The cell extracts (5mg of each lysate) were subjected to
SDS-PAGE according to Laemmli’s method (Laemmli, 1970) using
10% acrylamide under reducing conditions. The proteins in the SDS-
PAGE gels were transferred to PVDF membranes (Millipore, Bedford,
MA) for 2 hours at 2mAcm2 using a transfer buffer (25mM Tris and
200mM glycine) without methanol. The membranes were blocked
by incubation in TBST (20mM Tris-HCl buffer pH 8.0, 0.15M NaCl,
and 0.1% Tween 20) with 10% skim milk. They were then incubated
with either affinity-purified antibodies (tyrosinase, Tyrp1;
0.5 mgml1) or serum (LGP85: 1:3000 dilution, a-tubulin: 1:1000
dilution), according to standard procedures. The immunoreactive
bands were detected using an enhanced chemiluminescence
detection kit (Pharmacia Biotech).
Northern blotting
Total RNA was isolated from lysates of B16 cells incubated with
inulavosin (5, 10, 15 mM) or without drug using RNAZol (Ambion,
Austiin, TX). Total RNA (10mg) was separated by 1.1% agarose/
formaldehyde gel electrophoresis and transferred to a Zeta probe GT
membrane (Bio-Rad). The probes for tyrosinase and Tyrp1 were
labeled using a Random Primer Labeling Kit (TAKARA, Tokyo,
Japan). After prehybridization (42 1C, 4 hours), the membrane was
hybridized overnight with probe and soaked in 1 SSC, 0.1% SDS
(3 times, room temperature), then washed with 1 SSC, 0.1% SDS
(15minutes, room temperature); 1 SSC, 0.1% SDS (4 15minutes,
65 1C); 0.5 SSC, 0.1% SDS (15minutes, 65 1C); and 0.1 SSC,
0.1% SDS (3 15minutes, 65 1C). The membrane was then exposed
to film for 72 hours at 80 1C.
Cell fixation and immunofluorescence
B16 melanoma cells were cultured on the coverslips coated with
0.1% gelatin (Chemicon, Temecula, CA) and then fixed with 4%
paraformaldehyde for 30minutes on ice and permeabilized with
0.05% saponin (Sigma-Aldrich). Fixed cells were quenched with
50mM NH4Cl for 10minutes and then washed in PBS for 15minutes.
After blocking in 1% BSA in PBS, the cells were incubated with
primary antibodies in 1% BSA/PBS for 1 hour, washed with PBS, and
then incubated with secondary antibodies for 30minutes.
Electron microscopy analyses
Conventional electron microscopy I. B16 melanoma cells were
fixed at room temperature for 1 hour with 4% paraformaldehyde
(Sigma-Aldrich) and 1.0% glutaraldehyde (Nacalai Tesque, Kyoto,
Japan) in 0.2M HEPES-KOH buffer (pH 7.4), and processed for an
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ultrastructural analysis as described earlier (Yokota et al., 2000)
(Figure 2).
Conventional electron microscopy II. Cells were fixed in 2.5%
glutaraldehyde in 0.1 M Na-phosphate buffer, pH 7.4 for 1 hour
(Figure 7). The cells were washed in the same buffer three times, and
were post-fixed in 1% OsO4 in 0.1 M cacodylate buffer pH 7.4 for
1 hour. After washing in distilled water, cells were dehydrated and
embedded in epoxy resin. As described earlier (Yamamoto et al.,
1996), ultra-thin sections were observed under a Hitachi H7600
electron microscope (Hitachi, Tokyo, Japan) after heavy metal
staining.
Immunoelectron microscopy. Cells were fixed 4% paraformal-
dehyde in 0.1 M phosphate buffer (pH 7.4) for 30minutes and
processed for ultra-thin cryosectioning (Figure 7). Frozen sections
were incubated with anti-tyrosinase rabbit pAb alone or with this
antibody and anti-lamp1 rat MAb, followed by incubation with anti-
rabbit IgG coupled with 10 nm gold particles for the former, or a
mixture of anti-rabbit IgG coupled with 10 nm gold particles and
anti-rat IgG coupled with 5 nm gold particles. Sections were
negatively stained, embedded in polyvinyl alcohol (Tokuyasu,
1989), and examined under a Hitachi H7600 electron microscope.
Imaging. All of the immunofluorescence images were observed
using a Leica DMRB microscope (Wetzlar, Germany), acquired
using a cooled CCD camera, MicroMAX (Princeton Instruments,
Trenton, NJ), and digitally processed using IPlab Software (Scana-
lytics, Fairfax, VA). All images were assembled and labeled using
Adobe Photoshop (Adobe Systems, Mountain View, CA).
Pulse-chase experiments. B16 melanoma cells were grown in a
3.5-cm dish in the presence or absence of 15 mM inulavosin for
24 hours, after which they were metabolically labeled for 5minutes
with 100 mCiml1 [35S]methionine/cysteine (EXPRESS Protein
Labeling Mix, [35S]-Easy Tag, New England Nuclear, Boston, MA)
and chased with the medium for specific periods. During the pulse
and chase periods, the cells were cultured in the medium containing
either inulavosin alone or inulavosin and the indicated concentra-
tion of inhibitors. The labeled cells were lysed with lysis buffer and
centrifuged in a microfuge for 10minutes to remove insoluble
compounds. The cell extracts were subsequently processed for
immunoprecipitation with each antibody coupled with protein A-
sepharose. The immunoprecipitates were analyzed by SDS-PAGE
using 10% acrylamide under reducing conditions. Radioactive
bands were detected with a Fuji BAS 1000 Imaging Analyzer (Fuji,
Tokyo, Japan).
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We thank Dr T. August of Johns Hopkins University and Dr K. Furuta of
National Cancer Hospital for providing the MAb specific for mouse lamp1
(1D4B). We are also grateful to Dr D. Murphy of Johns Hopkins University for
providing the pAb to a-tubulin. We thank Dr T. Ueno of Juntendo University
for providing the pAb specific for Pmel17. This study was supported in part by
grants from the Ministry of Labor, Health, and Welfare of Japan and the
Ministry of Education, Science, Sports, and Culture of Japan.
SUPPLEMENTARY MATERIAL
Figure S1. Epoxomicin and Lactacystin function in B16 melanoma cells.
REFERENCES
Ando H, Funasaka Y, Oka M, Ohashi A, Furumura M, Matsunaga N et al.
(1999) Possible involvement of proteolytic degradation of tyrosinase in
the regulatory effect of fatty acids on melanogenesis. J Lipid Res
40:1312–6
Ando H, Watabe H, Valencia JC, Yasumoto K, Furumura M, Funasaka Y et al.
(2004) Fatty acids regulate pigmentation via proteasomal degradation of
tyrosinase: a new aspect of ubiquitin-proteasome function. J Biol Chem
279:15427–33
Berson JF, Harper DC, Tenza D, Raposo G, Marks MS (2001) Pmel17 initiates
premelanosome morphogenesis within multivesicular bodies. Mol Biol
Cell 12:3451–64
Bonifacino JS, Traub LM (2003) Signals for sorting of transmembrane
proteins to endosomes and lysosomes. Annu Rev Biochem 72:
395–447
Calvo PA, Frank DW, Bieler BM, Berson JF, Marks MS (1999) A cytoplasmic
sequence in human tyrosinase defines a second class of di-leucine-based
sorting signals for late endosomal and lysosomal delivery. J Biol Chem
274:12780–9
Chapuy B, Tikkanen R, Mu¨hlhausen C, Wenzel D, von Figura K, Ho¨ning S
(2008) AP-1 and AP-3 mediate sorting of melanosomal and lysosomal
membrane proteins into distinct post-Golgi trafficking pathways. Traffic
9:1157–72
del Marmol V, Beermann F (1996) Tyrosinase and related proteins in
mammalian pigmentation. FEBS Lett 381:165–8
Dell’Angelica EC (2003) Melanosome biogenesis: shedding light on the origin
of an obscure organelle. Trends Cell Biol 13:503–6
Fujita H, Ezaki J, Noguchi Y, Kono A, Himeno M, Kato K (1991) Isolation
and sequencing of a cDNA clone encoding 85 kDa sialoglycoprotein in
rat liver lysosomal membranes. Biochem Biophys Res Commun
178:444–52
Fujita H, Saeki M, Yasunaga K, Ueda T, Imoto T, Himeno M (1999) In vitro
binding study of adaptor protein complex (AP-1) to lysosomal targeting
motif (LI-motif). Biochem Biophys Res Commun 255:54–8
Fujita H, Sasano E, Yasunaga K, Furuta K, Yokota S, Wada I et al. (2001)
Evidence for distinct membrane traffic pathways to melanosomes and
lysosomes in melanocytes. J Investig Dermatol Symp Proc 6:19–24
Groux-Degroote S, van Dijk SM, Wolthoorn J, Neumann S, Theos AC, De
Mazie`re AM et al. (2008) Glycolipid-dependent sorting of melanosomal
from lysosomal membrane proteins by lumenal determinants. Traffic
9:951–63
Gruenberg J (2003) Lipids in endocytic membrane transport and sorting. Curr
Opin Cell Biol 15:382–8
Gruenberg J, Maxfield FR (1995) Membrane transport in the endocytic
pathway. Curr Opin Cell Biol 7:552–63
Gruenberg J, Stenmark H (2004) The biogenesis of multivesicular endosomes.
Nat Rev Mol Cell Biol 5:317–23
Hall AM, Krishnamoorthy L, Orlow SJ (2003) Accumulation of tyrosinase in
the endolysosomal compartment is induced by U18666A. Pigment Cell
Res 16:149–58
Hall AM, Orlow SJ (2005) Degradation of tyrosinase induced by phe-
nylthiourea occurs following Golgi maturation. Pigment Cell Res
18:122–9
Hoashi T, Muller J, Vieira WD, Rouzaud F, Kikuchi K, Tamaki K et al. (2006)
The repeat domain of the melanosomal matrix protein PMEL17/GP100 is
required for the formation of organellar fibers. J Biol Chem 281:
21198–21208
Honing S, Sandoval IV, von Figura K (1998) A di-leucine-based motif in the
cytoplasmic tail of LIMP-II and tyrosinase mediates selective binding of
AP-3. EMBO J 17:1304–14
Huizing M, Sarangarajan R, Strovel E, Zhao Y, Gahl WA, Boissy RE (2001) AP-
3 mediates tyrosinase but not TRP-1 trafficking in human melanocytes.
Mol Biol Cell 12:2075–85
1498 Journal of Investigative Dermatology (2009), Volume 129
H Fujita et al.
Inulavosin Leads Tyrosinase to Lysosomes
Ichikawa S, Nakajo N, Sakiyama H, Hirabayashi Y (1994) A mouse B16
melanoma mutant deficient in glycolipids. Proc Natl Acad Sci USA
91:2703–7
Kantheti P, Qiao X, Diaz ME, Peden AA, Meyer GE, Carskadon SL et al. (1998)
Mutation in AP-3 delta in the mocha mouse links endosomal transport to
storage deficiency in platelets, melanosomes, and synaptic vesicles.
Neuron 21:111–22
Kornfeld S, Mellman I (1989) The biogenesis of lysosomes. Annu Rev Cell Biol
5:483–525
Laemmli UK (1970) Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature 227:680–5
Marks MS, Seabra MC, Raposo G, Tenza D, Murphy DM, Berson JF (2001)
The melanosome: membrane dynamics in black and white. Nat Rev Mol
Cell Biol 2:738–48
Ni-Komatsu L, Orlow SJ (2008) Chemical genetic screening identifies tricyclic
compounds that decrease cellular melanin content. J Invest Dermatol
128:1236–47
Niwa K, Tanaka R, Murase H, Ishikawa T, Fujita H, Himeno M et al. (2003)
Two lysosomal membrane proteins, LGP85 and LGP107, are delivered
to late endosomes/lysosomes through different intracellular routes after
exiting from the trans-Golgi network. Biochem Biophys Res Commun
301:833–40
Okazaki K, Uzuka M, Morikawa F, Toda K, Seiji M (1976) Transfer
mechanism of melanosomes in epidermal cell culture. J Invest Dermatol
67:541–7
Orlow SJ (1995) Melanosomes are specialized members of the lysosomal
lineage of organelles. J Invest Dermatol 105:3–7
Piper RC, Katzmann DJ (2007) Biogenesis and function of multivesicular
bodies. Annu Rev Cell Dev Biol 23:519–47
Raposo G, Marks MS (2002) The dark side of lysosome-related organelles:
specialization of the endocytic pathway for melanosome biogenesis.
Traffic 3:237–48
Raposo G, Marks MS (2007) Melanosomes–dark organelles enlighten
endosomal membrane transport. Nat Rev Mol Cell Biol 8:786–97
Raposo G, Tenza D, Murphy DM, Berson JF, Marks MS (2001) Distinct protein
sorting and localization to premelanosomes, melanosomes, and lyso-
somes in pigmented melanocytic cells. J Cell Biol 152:809–24
Richmond B, Huizing M, Knapp J, Koshoffer A, Zhao Y, Gahl WA et al. (2005)
Melanocytes derived from patients with Hermansky-Pudlak Syndrome
types 1, 2, and 3 have distinct defects in cargo trafficking. J Invest
Dermatol 124:420–7
Robinson MS, Bonifacino JS (2001) Adaptor-related proteins. Curr Opin Cell
Biol 13:444–53
Setty SR, Tenza D, Truschel ST, Chou E, Sviderskaya EV, Theos AC et al. (2007)
BLOC-1 is required for cargo-specific sorting from vacuolar early
endosomes toward lysosome-related organelles. Mol Biol Cell 18:768–80
Sillence DJ, Puri V, Marks DL, Butters TD, Dwek RA, Pagano RE et al. (2002)
Glucosylceramide modulates membrane traffic along the endocytic
pathway. J Lipid Res 43:1837–45
Simmen T, Schmidt A, Hunziker W, Beermann F (1999) The tyrosinase tail
mediates sorting to the lysosomal compartment in MDCK cells via a di-
leucine and a tyrosine-based signal. J Cell Sci 112:45–53
Solano F, Briganti S, Picardo M, Ghanem G (2006) Hypopigmenting agents:
an updated review on biological, chemical and clinical aspects. Pigment
Cell Res 19:550–71
Sprong H, Degroote S, Claessens T, van Drunen J, Oorschot V, Westerink BH
et al. (2001) Glycosphingolipids are required for sorting melanosomal
proteins in the Golgi complex. J Cell Biol 155:369–80
Theos AC, Tenza D, Martina JA, Hurbain I, Peden AA, Sviderskaya EV
et al. (2005) Functions of adaptor protein (AP)-3 and AP-1 in
tyrosinase sorting from endosomes to melanosomes. Mol Biol Cell
16:5356–72
Theos AC, Truschel ST, Tenza D, Hurbain I, Harper DC, Berson JF et al.
(2006) A lumenal domain-dependent pathway for sorting to intralumenal
vesicles of multivesicular endosomes involved in organelle morphogen-
esis. Dev Cell 10:343–54
Tokuyasu KT (1989) Use of poly(vinylpyrrolidone) and poly(vinyl alcohol) for
cryoultramicrotomy. Histochem J 21:163–71
van der Goot FG, Gruenberg J (2002) Oiling the wheels of the endocytic
pathway. Trends Cell Biol 12:296–9
Vijayasaradhi S, Xu Y, Bouchard B, Houghton AN (1995) Intracellular sorting
and targeting of melanosomal membrane proteins: identification of
signals for sorting of the human brown locus protein, gp75. J Cell Biol
130:807–20
Wei ML (2006) Hermansky-Pudlak syndrome: a disease of protein trafficking
and organelle function. Pigment Cell Res 19:19–42
Xu Y, Set aluri V, Takechi Y, Houghton AN (1997) Sorting and secretion of a
melanosome membrane protein, gp75/TRP1. J Invest Dermatol 109:
788–795
Yamamoto A, Masaki R, Tashiro Y (1996) Formation of crystalloid
endoplasmic reticulum in COS cells upon overexpression of microsomal
aldehyde dehydrogenase by cDNA transfection. J Cell Sci 109:
1727–1738
Yang W, Li C, Ward DM, Kaplan J, Mansour SL (2000) Defective organellar
membrane protein trafficking in Ap3b1-deficient cells. J Cell Sci
113:4077–86
Yokota S, Kamijo K, Oda T (2000) Aggregate formation and degradation of
overexpressed wild-type and mutant urate oxidase proteins. Quality
control of organelle-destined proteins by the endoplasmic reticulum.
Histochem Cell Biol 114:433–46
Yoshida T, Mori K, He G (1995) Inulavosin, a New Thymol Dimer with
Piscicidal Activity from Inula nervosa. Heterocycles 41:1923–6
www.jidonline.org 1499
H Fujita et al.
Inulavosin Leads Tyrosinase to Lysosomes
